What Is Entera Bio Ltd. (ENTX) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Entera Bio Ltd.'s intrinsic value is estimated at $1.02, suggesting the stock is overvalued at its current price of $1.78. With 9 out of 11 models flagging downside (-42.6% average return), the market may be pricing in unsustainable growth. Notably, Regime Cross sees the most upside at +216.3% (fair value: $5.63), while ML-RIV is the most conservative at -98.6% ($0.03). The spread between these extremes — +314.9% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About ENTX?
11 of 13 models are currently active for ENTX. Of these, 2 models suggest upside while 9 models suggest overvaluation. The Bayesian DCF estimates ENTX's intrinsic value at $0.29, implying -83.5% downside from the current price. See which stocks rank higher →
How Does ENTX Rank in Biological Products, (No Diagnostic Substances)?
Among 134 Biological Products, (No Diagnostic Substances) stocks, ENTX ranks #45 by Quality of Company score. CirclFi's QOC score of 5.9/10 evaluates 32 fundamental signals. A score of 5.9 reflects mixed fundamentals.
See all Most Undervalued Biological Products, (No Diagnostic Substances) Stocks →
Entera Bio Ltd. operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.
Is ENTX a Value Trap?
CirclFi's Value Trap algorithm assigns ENTX a score of 38/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
11 of 13 models are active for Entera Bio Ltd.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Entera Bio Ltd. is rated at 5.9/10. This solid-tier score maintains reasonable quality metrics with some areas for improvement.
The gap between the most bullish and bearish model spans +314.9% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every ENTX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across ENTX's 11 active models, average confidence is 25%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad